Key result
SMuRF-less STEMI patients had a significantly higher risk of in-hospital all-cause mortality compared to SMuRF-positive patients after adjusting for age, creatinine, and hemoglobin (HR 1.54).
Why the study?
Data on SMuRF-less AMI patients were limited to STEMI and predominantly Caucasian cohorts, leaving prevalence and mortality patterns across STEMI and NSTEMI in multiethnic Asian populations unclear.
Does the absence of standard modifiable cardiovascular risk factors (SMuRF-less) impact mortality outcomes in acute myocardial infarction patients undergoing PCI?
Cohort (n=20,486)
Yes
Does the absence of standard modifiable cardiovascular risk factors (SMuRF-less) impact mortality outcomes in acute myocardial infarction patients undergoing PCI?
Hazard Ratio: 1.54 (95% CI 1.12–2.11)
SMuRF-less STEMI patients present with higher disease severity and have an increased risk of mortality, suggesting a need for intensive secondary prevention strategies in this population.
SMuRF-less STEMI patients warrant closer monitoring; extends evidence of excess mortality risk to multiethnic Asian populations.
Background: Acute myocardial infarction (AMI) cases have decreased in part due to the advent of targeted therapies for standard modifiable cardiovascular disease risk factors (SMuRF). Recent studies have reported that ST-elevation myocardial infarction (STEMI) patients without SMuRF (termed "SMuRF-less") may be increasing in prevalence and have worse outcomes than "SMuRF-positive" patients. As these studies have been limited to STEMI and comprised mainly Caucasian cohorts, we investigated the changes in the prevalence and mortality of both SMuRF-less STEMI and non-STEMI (NSTEMI) patients in a multiethnic Asian population. Methods: We evaluated 23,922 STEMI and 62,631 NSTEMI patients from a national multiethnic registry. Short-term cardiovascular and all-cause mortalities in SMuRF-less patients were compared to SMuRF-positive patients. Results: The proportions of SMuRF-less STEMI but not of NSTEMI have increased over the years. In hospitals, all-cause and cardiovascular mortality and 1-year cardiovascular mortality were significantly higher in SMuRF-less STEMI after adjustment for age, creatinine, and hemoglobin. However, this difference did not remain after adjusting for anterior infarction, cardiopulmonary resuscitation (CPR), and Killip class. There were no differences in mortality in SMuRF-less NSTEMI. In contrast to Chinese and Malay patients, SMuRF-less patients of South Asian descent had a two-fold higher risk of in-hospital all-cause mortality even after adjusting for features of increased disease severity. Conclusion: SMuRF-less patients had an increased risk of mortality with STEMI, suggesting that there may be unidentified nonstandard risk factors predisposing SMuRF-less patients to a worse prognosis. This group of patients may benefit from more intensive secondary prevention strategies to improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Sia et al. (2022) conducted a cohort in Acute Myocardial Infarction (STEMI and NSTEMI) (n=20,486). Absence of standard modifiable cardiovascular risk factors (SMuRF-less) vs. Presence of at least one standard modifiable cardiovascular risk factor (SMuRF-positive) was evaluated on In-hospital all-cause mortality (STEMI, adjusted for age, creatinine, and hemoglobin) (HR 1.54, 95% CI 1.12-2.11). SMuRF-less STEMI patients had a significantly higher risk of in-hospital all-cause mortality compared to SMuRF-positive patients after adjusting for age, creatinine, and hemoglobin (HR 1.54).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: